Moderna COVID-19 Vaccine
for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

- If a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

### Children who turn from age 5 to age 6 years

**Recommended:** Children who started a primary series and turned from age 5 to age 6 years before completion of the series should receive:

- **Dose 1 (Age 5):** 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border)
- **Dose 2 (Age 6):** 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)

**Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

Either dose may be:
- 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border), or
- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)
Children who turn from age 11 years to 12 years

**Recommended:** Children who started a primary series and turned from age 11 to age 12 years before completion of the series should receive:

- **Dose 1 (Age 11):** 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)
- **Dose 2 (Age 12):** 0.50 mL (100 mcg) of the product authorized for children ages 12 years and older (red cap/light blue label border)

**Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Either dose may be:
- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border), OR
- 0.50 mL (100 mcg) of the product authorized for children ages 12–17 years (red cap/light blue label border)